Development and validation of a novel immune-related prognostic signature in lung squamous cell carcinoma patients

Lung Squamous Cell Carcinoma (LUSC) is an aggressive malignancy with limited therapeutic options. The response to immune therapy is a determining factor for the prognosis of LUSC patients. This study aimed to develop a reliable immune-related prognostic signature in LUSC. We extracted gene expressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xianyu, Zhao, Deze, Shan, Yunhan, Cui, Weifang, Xie, Qun, Jiang, Junjie, Peng, Wei, Zhang, Chunfang, Duan, Chaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715950/
https://www.ncbi.nlm.nih.gov/pubmed/36456645
http://dx.doi.org/10.1038/s41598-022-23140-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715950/
https://www.ncbi.nlm.nih.gov/pubmed/36456645
http://dx.doi.org/10.1038/s41598-022-23140-w

Ejemplares similares